In contrast to our previous in vitro study which showed an advantage of EGFR-targeting for increasing the absorbed dose and cytotoxicity of 177Lu-labeled radiation nanomedicines on MDA-MB-468 cells (Yook et al. 2015), in vivo in mice with s.c. MDA-MB-468 tumours, EGFR-targeting was not required. Here, EGFR is linked to neoplasm.